In a statement, Poonam Khetrapal Singh stated, "Antimicrobial resistance (AMR) continues to pose a significant challenge to global public health, with devastating effects on the efficacy of essential medicines and the ability to effectively treat infectious diseases."
Mumbai (Maharashtra) [India], November 24 (ANI/NewsVoir): LumiraDx Healthcare Private Limited, a next-generation point of care diagnostics testing company announced it has launched its highly sensitive C-Reactive Protein (CRP) point of care antigen test across India.
New global estimates show that in 2019, nearly 5 million human deaths worldwide were associated with bacterial AMR, of which 1.3 million human deaths were directly attributable to bacterial AMR. In a high-impact scenario, AMR will reduce global annual GDP by 3.8 per cent by 2050.